Filing Flows › Endovia Health Sciences (EDVA) › Q1 2026
Endovia Health Sciences (EDVA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 20, 2026
Endovia Health Sciences (EDVA) reported revenue of $4K for the first quarter 2026 (Q1 2026), -94% from a year earlier.
Endovia Health Sciences, Q1 2026: revenue $4K (-94% year over year), net earnings $2.5M, operating cash flow −$930K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4K | — | -94% |
| Operating profit | −$979K | — | — |
| Net earnings | $2.5M | — | — |
| Operating cash flow | −$930K | — | — |
What changed
Revenue was $4K in Q1 2026, down 94% year over year.
Gross margin was 43.8%, up 6.5 points from Q1 2025. Operating costs exceeded revenue by $1.0M, an operating margin of -23176.4%. Operating expenses fell 42% while revenue fell 94%. Net earnings were −$2.1M. The effective tax rate was 0.0%. Non-operating items added $3.5M, 139% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$930K. Non-cash charges added back $2K of depreciation and $177K of share-based compensation. Working capital and other items used $3.6M.
Questions
What was Endovia Health Sciences' revenue in the first quarter 2026?
Endovia Health Sciences (EDVA) reported revenue of $4K for the first quarter 2026 (Q1 2026), -94% from a year earlier.